Markets
BSE See NSE See 52,653.07
209.36 (0.4%)

Wipro joins hands with Transcell Oncologics; makes new 52-week high

Anthony Fernandes
/ Categories: Trending, DSIJ News
Rate this article:
4.8
Wipro joins hands with Transcell Oncologics; makes new 52-week high

IT major, Wipro Limited informed the exchanges that it has partnered with Transcell Oncologics in a bid to transform vaccine safety assessment using artificial intelligence.  

The partnership brings together, Transcell’s innovative stem cell technology with the advanced artificial intelligence capabilities of Wipro HOLMES, to improve the safety of global vaccine immunisation programmes.  

At present, vaccine safety assessment includes testing on animals to measure adverse impacts. Wipro believes that by using Wipro HOLMES instead, researchers & biopharmaceutical companies will have a new and fully viable solution that is capable of predicting adverse neurovirulent impacts resulting from vaccinations.   

This will be the first in a number of next-gen solutions that the partnership will bring to the table to determine the safety & efficacy of a wide range of products, ranging from vaccines to prescription medications and cosmetics.   

At 2.42 pm on Thursday, the shares of Wipro Limited were trading at Rs 513.50, up by 4.63 per cent or Rs 22.70 per share, against a 0.42 per cent gain in the benchmark index. The 52-week high of the company is recorded at Rs 514.85 while its 52-week low is Rs 178.20 on BSE.   

Previous Article Subex soars over 13 per cent on partnering with Snowflake
Next Article Investing for first time investors
Please login or register to post comments.

Get A Call From Industry Experts

Send Otp

   I authorize DSIJ Pvt Ltd to contact me. This will override registry on the NDNC.

DSIJ MINDSHARE

1345Last

Knowledge

1345Last